Acadia Pharmaceuticals (ACAD) Current Leases (2011 - 2012)

Acadia Pharmaceuticals (ACAD) recorded quarterly Current Leases of $3000.0 in Q3 2012, down 76.92% quarter-over-quarter from $13000.0 in Q2 2012.

Acadia Pharmaceuticals (ACAD) Current Leases (2011 - 2012) Analysis & Trends

Acadia Pharmaceuticals' Current Leases history runs 2 years deep, the most recent figure standing at $3000.0 for Q3 2012.

In Q3 2012, Current Leases changed N/A year-over-year to $3000.0; the TTM figure through Sep 2012 stood at $3000.0 (changed N/A YoY), while the FY2011 annual figure was $32000.0, changed N/A from the prior year.
Current Leases was $3000.0 for Q3 2012 at Acadia Pharmaceuticals, down from $13000.0 in the prior quarter.
In the past five years, Current Leases ranged from a high of $32000.0 in Q4 2011 to a low of $3000.0 in Q3 2012.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	42,980.09
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	83,991.00
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	7.40 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Acadia Pharmaceuticals	3.68 Bn	2.83 Bn	243.27 Mn	-

Download Data